Table 1.
Summary of 14 randomized controlled trials included in the meta-analysis.
| Study | Author | Year | Study Group (regime and no. of Pts.) |
Control Group (regime and no. of Pts.) |
Inclusion criteria | ||
|---|---|---|---|---|---|---|---|
| CA184-041 | Lynch et al. 25 | 2012 | Ipi+Chemo | 70 | Chemo alone | 66 | Stage IIIB or IV NSCLC |
| KEYNOTE 021 | Langer et al. 19 | 2016 | Pembro+Chemo | 60 | Chemo alone | 63 | Stage IIIB or IV, non-squamous NSCLC without targetable genetic aberration |
| NCT01285609 | Govindan et al. 26 | 2017 | Ipi+Chemo | 388 | Chemo alone | 361 | stage IV or recurrent squamous NSCLC |
| IMpower 150 | Socinski et al. 20 | 2018 | Atezo+Chemo | 400 | Chemo alone | 400 | Stage IIIB or IV, non-squamous NSCLC without targetable genetic aberration |
| IMpower 131 | Jotte et al. 22 | 2018 | Atezo+Chemo | 343 | Chemo alone | 340 | Stage IV, squamous NSCLC without |
| IMpower 132 | Papadimitrakopoulou et al. 23 | 2018 | Atezo+Chemo | 292 | Chemo alone | 286 | Stage IV non-squamous NSCLC without targetable genetic aberration |
| KEYNOTE 407 | Paz-Ares et al. 21 | 2018 | Pembro+Chemo | 278 | Chemo alone | 281 | Stage IV, squamous NSCLC |
| KEYNOTE 189 | Gandhi et al. 18 | 2018 | Pembro+Chemo | 410 | Chemo alone | 206 | Stage IV non-squamous NSCLC without targetable genetic aberration |
| IMpower 130 | West et al. 24 | 2019 | Atezo+Chemo | 473 | Chemo alone | 232 | Stage IV, non-squamous NSCLC without targetable genetic aberration |
| PACIFIC | Antonia et al. 31, 32 | 2018 | Durva+Chemo | 476 | Chemo alone | 237 | stage III, unresectable NSCLC |
| KEYNOTE 024 | Reck et al. 29 | 2016 | Pembro alone | 154 | Chemo alone | 151 | Stage IIIB or IV, NSCLC without targetable genetic aberration but with a PD-L1 tumor-expression level of 50% or more |
| CheckMate 026 | Carbone et al. 27 | 2017 | Nivo alone | 271 | Chemo alone | 270 | Stage IV or recurrent NSCLC without targetable genetic aberration but with a PD-L1 tumor-expression level of 5% or more |
| CheckMate 227 | Hellmann et al. 28 | 2018 | Nivo+Ipi | 139 | Chemo alone | 160 | Stage IV or recurrent NSCLC without targetable genetic aberration, with a high tumor mutational burden (≥10 mutations per megabase) |
| KEYNOTE 042 | Mok et al. 30 | 2018 | Pembro alone | 637 | Chemo alone | 637 | Stage IV or recurrent NSCLC without targetable genetic aberration but with a PD-L1 tumor-expression level of 1% or more |
Abbreviations: Pts -patients, Pembro- Pembrolizumab, Atezo -Atezolizumab, Nivo- Nivolumab, Ipi- Ipilimumab, Durva-Durvalumab, Chemo- Chemotherapy